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SUMMARY
Chagas disease (CD) is caused by the intracellular protozoan parasite Trypanosoma cruzi and aﬀects more than 10 million
people in poor areas of Latin America. There is an urgent need for alternative drugs with better safety, broader eﬃcacy,
lower costs and shorter time of administration. Thus the biological activity of viniconazole, a chloroaryl-substituted
imidazole was investigated using in vitro and in vivo screening models of T. cruzi infection. Ultrastructural ﬁndings
demonstrated that the most frequent cellular damage was associated with plasma membrane (blebs and shedding events),
Golgi (swelling aspects) and the appearance of large numbers of vacuoles suggesting an autophagic process. Our data
demonstrated that although this compound is eﬀective against bloodstream and intracellular forms (16 and 24 μM,
respectively) in vitro, it does not present in vivo eﬃcacy. Due to the urgent need for novel agents against T. cruzi, the
screening of natural and synthetic products must be further supported with the aim of ﬁnding more selective and aﬀordable
drugs for CD.
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INTRODUCTION
Neglected tropical diseases, primarily aﬀecting the
poorest individuals living in developing countries,
account for up to 90% of the global disease burden
but get less than 10% of the research funds for
new drug development approaches by both pharma-
ceutical industry and the public sector (Nour et al.
2009). Chagas disease (CD) is the sixth most im-
portant tropical infection faced by many Latin
American countries (Martins-Melo et al. 2012).
This parasitic disease caused by the ﬂagellated proto-
zoan organism, Trypanosoma cruzi still demands
safer and more selective medicines since the current
drugs (benznidazole and nifurtimox) present several
undesirable characteristics such as long term of
administration (30–60 days), high levels of adverse
eﬀects and limited eﬃcacy especially during the later
chronic phase (Soeiro et al. 2010). In the last few
years of experimental chemotherapy investigation,
some natural products like sesquiterpene lactones
(SL) (Schmidt et al. 2012a, b) and synthetic agents
like arylimidamides (Soeiro et al. 2013a) and inhibi-
tors of fungal sterol 14α-demethylase (CYP51) have
been reported as promising trypanocidal agents
(Urbina, 2009; Hargrove et al. 2012). Among the
last class of compounds, antifungal CYP51 inhibitors
posaconazole and ravuconazole are ﬁnally in clinical
trials for CD but the development of cheaper and
more eﬃcient anti-T. cruzi chemotherapies is still
needed (Soeiro et al. 2013b). In this context, our
present aim was to investigate through in vitro and
in vivo studies the biological eﬀect of the chloroaryl-
substituted imidazole viniconazole with the goal of
identifying novel anti-T. cruzi leads for possible
future development into alternative therapies for CD.
MATERIALS AND METHODS
Compounds
Viniconazole (Fig. 1) was kindly received from
Dr M. Witschel, BASF (Ludwigshafen, Germany).
Benznidazole (Bz, Laboratório Farmacêutico do
Estado de Pernambuco – LAFEPE, Brazil) was
used as the reference drug (Batista et al. 2010).
Stock solutions of the compounds (3·3 mM) were
prepared in dimethyl sulfoxide (DMSO). Fresh ﬁnal
solvent concentration in the assays never exceeded
0·6%, which is not toxic for both parasites and
mammalian cells. For in vivo studies, a stock solution
of each compound was ﬁrst prepared in DMSO and
then diluted using sterile distilled water. The ﬁnal
concentration of DMSO never exceeded 10%, a
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concentration which is well tolerated by mice
(Da Silva et al. 2012).
Cell cultures
Toxicity and infection assays: primary cultures of
cardiac cells (CM) were obtained from mouse em-
bryos as reported (Meirelles et al. 1986). The cultures
were maintained in Dulbecco’s modiﬁed Eagle’s
medium (DMEM) supplemented with 10% horse
serum, 5% fetal bovine serum (FBS), 2·5 mM CaCl2,
1 mM L-glutamine and 2% chicken embryo extract.
Cell cultures were maintained at 37 °C in an atmos-
phere of 5% CO2 in air, and assays were run at least
three times in duplicates.
Parasites
The Y strain of T. cruzi was used throughout the ex-
periments. Bloodstream trypomastigotes (BT) were
harvested by heart puncture from T. cruzi-infected
Swiss mice at the day of parasitaemia peak (Meirelles
et al. 1986). Intracellular amastigotes lodged within
cardiac cell cultures were employed as reported
(Da Silva et al. 2012).
In vitro cytotoxicity assays
Uninfected cardiac cultures were incubated for 24
and 48 h at 37 °C in the presence or absence of each
compound diluted in DMEM. The cardiac cell
morphology and spontaneous contractibility were
evaluated by light microscopy. The cell death rates
were measured by MTT (3-(4,5-dimethyl-2-thiazo-
lyl)-2,5-diphenyl-2H-tetrazolium bromide – Sigma
Aldrich) colorimetric assay, for the determination of
EC50 (compound concentration that reduces 50% of
cellular viability) as reported (Batista et al. 2011).
Trypanocidal analysis
The BT were incubated at 37 °C for 24 h in the pres-
ence of increasing non-toxic concentrations of the
tested compounds diluted in RPMI 1640 medium
(Roswell Park Memorial Institute, Sigma Aldrich,
USA) supplemented with 5% FBS. Death rates were
determined by light microscopy through direct quan-
tiﬁcation of the number of live parasites using a
Neubauer chamber, and the EC50 (compound con-
centration that reduces 50% of the number of the
treated parasites) calculated. For the analysis of
the eﬀect against intracellular amastigotes, after 24 h
of parasite–host cell interaction (10:1 parasite: CM
ratio), the infected cultures were washed to remove
free parasites and then incubated for another 48 h
with increasing but non-toxic doses of the com-
pound. The CM were maintained at 37 °C in an
atmosphere of 5% CO2 in air, and the medium was
replaced every 24 h. Then, untreated and treated
infected CM were ﬁxed and stained with Giemsa
solution and the mean number of infected host cells
and of parasites per infected cells scored as reported
(Da Silva et al. 2012). As light microscopy of un-
treated T. cruzi-infected cell cultures allows the
identiﬁcation of parasites through their typical nuclei
and kDNA structures, only those intracellular forms
that display these characteristic cellular elements
were considered as live/viable parasites (Da Silva
et al. 2012). Control samples included parasites and
infected cell cultures incubated solely with vehicle
solution (DMSO not exceeding 0·6%). The activity
of viniconazole was estimated by calculating the
infection index (percentage of infected cells times
the average number of intracellular amastigotes per
infected host cell). All in vitro assays were run at least
twice in duplicates.
Transmission electron microscopy (TEM) analy-
sis: BT treated or not for 2 h at 37 °C with the corres-
ponding EC50 value of the tested compound were
ﬁxed for 60min at 4 °C with 2·5% glutaraldehyde
and 2·5 mM CaCl2 in 0·1 M cacodylate buﬀer, pH 7·2
and post-ﬁxed for 1 h at 4 °C with 1% OsO4, 0·8%
potassium ferricyanide and 2·5 mM CaCl2 using this
same buﬀer. Samples were routinely processed for
TEM and examined in a Zeiss EM10C electron
microscope (Oberkochen, Germany) (Da Silva et al.
2008).
Acute toxicity for mice: Maximum tolerated dose
(MTD) was determined using female Swiss Webster
mice (20–23 g). On day 1, mice were treated with the
tested compound by i.p. or oral (p.o.) route at doses
ranging from 25–400mg kg−1 (Batista et al. 2010).
The animals were then continuously inspected
for toxic and sub-toxic symptoms according to
OECD (Organization for Economic Co-operation
and Development) guidelines. Forty-eight hours
after compound injection, the MTD values were
determined based on animal survival rates and
behaviour alterations (Da Silva et al. 2012).
Mice infection and treatment schemes
Male Swiss mice were obtained from the Fundação
Oswaldo Cruz (FIOCRUZ) animal facilities (Rio de
Janeiro, Brazil). Mice were housed at 5 animals per
cage and kept in a conventional room at 20–24 °C
Fig. 1. Structure of viniconazole.
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under a 12/12 h light/dark cycle. The animals were
provided with sterilized water and chow ad libitum.
Infection was performed by i.p. injection of 104
(Y strain) BT (Batista et al. 2010). The animals
(18–21 g) were divided into the following groups (ﬁve
mice per group): uninfected (non-infected and un-
treated); untreated (infected with T. cruzi but treated
only with vehicle); and treated (infected and treated –
i.p. and orally (p.o.) up to 100mg kg−1 day−1
viniconazole or 100mg kg−1 day−1 benznidazole).
Mice received two doses (0·1 mL via i.p.): the ﬁrst
one at 5 and the second one at 8 days post-infection
(dpi) according to a previously standardized protocol
designed for evaluating the eﬃcacy of a novel
trypanocidal compound in an experimental mouse
model of acute T. cruzi infection, running in parallel
with the reference drug benznidazole (Bz) (Batista
et al. 2010). For Bz treatment, infected mice received
0·2 mL oral dose (gavage) following the same
therapeutic scheme as described above. Only those
mice that presented positive parasitaemia were used
in these studies.
Parasitaemia, mortality rates and ponderal
curve analysis
Parasitaemia was individually checked by direct
microscopic counting of parasites in 5 μL of blood,
as described (Brener, 1962). At diﬀerent times, the
body weight of each animal was recorded and the
diﬀerent mouse groups compared. Mortality was
checked daily until 30 days post treatment and
expressed as percentage of cumulative mortality
(% CM) (Batista et al. 2010).
Histopathological analysis
For acute toxicity analysis, tissues (heart, spleen,
liver and kidneys) were removed after 48 h of
viniconazole administration (25–400mg kg−1), long-
itudinally cut, rinsed in ice-cold PBS, and ﬁxed in
Millonig–Rosman solution (10% formaldehyde in
PBS). The tissues were dehydrated and embedded
in paraﬃn. Sections (3 μm) were stained by routine
haematoxylin–eosin and analysed by light micro-
scopy as reported (Batista et al. 2010).
Ethics
All procedures were carried out in accordance
with the guidelines established by the FIOCRUZ
Committee of Ethics for the Use of Animals (CEUA
0028/09).
RESULTS
The trypanocidal in vitro activity of the chloroaryl-
substituted imidazole, viniconazole, screened against
BT showed a time and dose-dependent eﬀect,
exhibiting EC50 values of 16 μM after treatment
for 24 h at 37 °C (Fig. 2A). This compound was
also active against intracellular parasites, showing
EC50 = 24 μM, after 48 h of treatment (Fig. 2B), while
the incubation with cardiac cell cultures resulted
in EC50 = 90 μM (data not shown).
Aiming to identify the main cellular targets of
viniconazole, BT were exposed to this chloroaryl-
substituted imidazole and processed for routine
TEM. The ultrastructural studies showed that un-
treated parasites exhibited normal morphology
such as typical plasma membrane, mitochondrion,
nucleus and Golgi complex (Fig. 3A and B). When
BTs were treated, we observed an intense intracellu-
lar vacuolization displaying vesicles of diﬀerent sizes
and electron densities (Fig. 3C, H and I), myelin-like
ﬁgures (Fig. 3I, arrowhead) and endoplasmic reticu-
lum proﬁles surrounding intracellular components
(Fig. 3H, arrow). A great number of membrane blebs
and shedding events were present, discharging
cytoplasmic and membrane components (Fig. 3D,
E, G). Also, alterations in the membrane proﬁle were
found in the nuclei of the treated cells (Fig. 3E, inset),
besides a frequent and intense swelling of Golgi
elements (Fig. 3F and E).
Fig. 2. Eﬀect of viniconazole on bloodstream
trypomastigotes and amastigotes of Trypanosoma cruzi
(Y strain) in vitro. The activity was evaluated against the
two parasite forms of T. cruzi: (A) bloodstream forms
incubated at 37 °C for 2 and 24 h followed by the
determination of the percentage of dead parasites, and (B)
intracellular amastigote forms incubated at 37 °C for 48 h
followed by the determination of the infection index (II).
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Our ﬁrst in vivo step was to evaluate aspects of
acute toxicity of viniconazole aiming to determine
its MTD value in order to set and follow eﬃcacy
studies. Thus, Swiss female mice received vinicona-
zole via the i.p. and p.o. route (25mg kg−1 up to
400mg kg−1) and were followed for non-invasive
Fig. 3. Transmission electron microscopy analysis (A–C) of trypomastigotes exposed to viniconazole: (A,B) untreated
and (C–I) treated with EC50/24 h. Untreated parasites display typical morphology, while viniconazole-treated parasites
show mitochondrial swelling (Fig. 2C, H, G and I), intense intracellular vacuolization with a great number of membrane
blebs and with shedding of intracellular contents (Fig. 2D, E and G), with the occurrence of large multivesicular proﬁles
(Fig. 2C, D and H), swelling Golgi complex (Fig. 2 F and E), cytoplasmic myelin-like ﬁgures (Fig. 2I), and alterations
in the nuclear membrane (Fig. 2E inset).
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side eﬀects up to 48 h after injection. The adminis-
tration of the compound at all tested doses with both
routes of application did not: (a) cause alteration on
typical behaviour, (b) result in mortality, (c) induce
visible neurological disorders or (d) alter the body
weight gain (data not shown). However, histopathol-
ogy of liver, spleen, heart and kidney showed
major alterations in liver samples (Table 1). A dose-
dependent reactivity related to hepatic micro-
vacuolization and mononuclear inﬂammation was
observed mainly at doses >50mg kg−1 via the i.p.
route (Table 1, Fig. 4).
Next, the eﬃcacy of viniconazole was tested in
Swiss male mice inoculated with 104 bloodstream
parasites using a therapeutic scheme employing doses
administered once a day, at 5 and 8 dpi (correspond-
ing to the onset and parasitaemia peak, respectively in
this animal model). Bz treatment was run in parallel
using a standard protocol (100 mg kg−1 via p.o.),
following the same therapeutic scheme as described
above.
As expected for this experimental mouse model of
T. cruzi acute infection, infected and untreated
animals (untreated group) presented high parasitae-
mia and no animal survival (Fig. 5). When vinicona-
zole was administrated via the i.p. route, all doses
failed to reduce parasitaemia or protect against mor-
tality (all treated animals died even earlier than the
untreated group). Although gavage administration of
viniconazole gave a mild reduction in parasitaemia
peak levels (about 35%), all mice died (Fig. 5). As
expected, Bz completely suppressed the parasitaemia
and gave 100% survival (Fig. 5).
DISCUSSION
Our present aim was to investigate the potential
eﬃcacy and selectivity of a chloroaryl-substituted
imidazole named viniconazole against T. cruzi. In
fact, azoles are considered a primary target for clinical
and agricultural antifungal agents and are also well
known as eﬀective inhibitors ofT. cruzi infection and
development in vitro and in vivo due to their ability to
inhibit CYP51, an enzyme catalysing ergosterol pro-
duction (Urbina, 2009). Recent studies regarding the
direct inhibition of CYP51 activity across phylogeny,
including the human pathogens Trypanosoma brucei,
T. cruzi and Leishmania infantum, identiﬁed novel
protozoa-speciﬁc inhibitory scaﬀolds that are easy to
synthesize and nontoxic, and among them, the VNI
molecule ((R)-N-(1-(2,4-dichlorophenyl)-2-(1H-
imidazol-1-yl)ethyl)-4-(5-phenyl-1,3,4-oxadi-azol-2-
yl)benzamide) presented high antiprotozoan activity,
killing T. cruzi amastigotes at low nanomolar con-
centration, being able to suppress parasitaemia and
improve the survival rates of T. cruzi-infected mice
(Soeiro et al. 2013b; Villalta et al. 2013). Thus, in
view of the promising trypanocidal activity of azoles,
presently the eﬃcacy in vitro and in vivo of a novel
chloro-imidazole compound was investigated. Our
ﬁndings showed that viniconazole displayed a trypa-
nocidal in vitro eﬀect against both BT (EC50 = 16 μM)
and intracellular amastigotes (EC50 = 24 μM) loca-
lized within cardiac host cells, but presented a con-
siderable toxicity towards mammalian cell cultures,
leading to quite low selectivity indices (4 to 6).
Although in acute toxicity studies no mortality and
no major side eﬀects were observed through non-
invasive methods followed up to 48 h after vinicona-
zole injection, histopathology analysis demonstrated
liver reactivity especially at doses >50mg kg−1 by the
i.p. route. Also, it failed to reduce parasite burden
and protect against animal mortality using a highly
stringent mouse model of T. cruzi infection using
the Y strain. The administration of viniconazole
for only 2 days, by both i.p. and p.o. routes, using
doses of up to 100mg kg−1 day−1 led to similar
results as those found in the vehicle-treated group
while Bz 100mg kg−1 (p.o.) under the same thera-
peutic scheme suppressed parasitaemia and gave
100% of animal survival.
Transmission electron microscopy was also per-
formed aiming to show the most frequent alteration
triggered by viniconazole in BT. Our present data
showed intense damage to the membranes of the
treated parasites, especially plasma membrane (blebs
and shedding events) and Golgi (swelling aspects).
Also, a high number of vacuoles could be found in
treated bloodstream forms which associated to the
Table 1. Analysis of hematoxilin and eosin stained
liver samples collected from mice treated with
viniconazole
Doses
mg kg−1 Intraperitoneally Per oral
Vehicle – No* – No*
25 – Mild hepatocyte
microvacuolization
– Rare inﬂammatory
inﬁltrates
– Mild hepatocyte
microvacuolization
50 – Severe hepatocyte
microvacuolization
– Rare inﬂammatory
inﬁltrates
– Mild hepatocyte
microvacuolization
– Rare inﬂammatory
inﬁltrates
100 – Severe hepatocyte
microvacuolization
– Rare inﬂammatory
inﬁltrates
– Mild hepatocyte
microvacuolization
– Rare inﬂammatory
inﬁltrates
200 – Severe hepatocyte
microvacuolization
– Moderate
inﬂammatory
inﬁltrates
– Moderate hepatocyte
microvacuolization
– Rare inﬂammatory
inﬁltrates
400 – Severe hepatocyte
microvacuolization
– Moderate
inﬂammatory
inﬁltrates
– Moderate hepatocyte
microvacuolization
– Rare inﬂammatory
inﬁltrates
* No alteration.
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previous alterations suggesting an autophagic
process, although other biochemical approaches are
needed to conﬁrm these data. Autophagy induced by
pharmacological agents has been reported in trypa-
nosomatids. Helenalin and cynaropicrin, two SLs,
induce a strong vacuolization in Leishmania mexicana
and in T. cruzi that was associated with autophagic
processes (Barrera et al. 2008; Da Silva et al. 2012).
Besides autophagy, other types of programmed cell
death like apoptosis has been described when patho-
gens are exposed to diﬀerent pharmacological stimuli
triggered in African trypanosomes (Nibret et al.
2011) and Leishmania mexicana (Barrera et al.
2008) by natural agents like SL and through
synthetic compounds like diamidines in T. cruzi
(De Souza et al. 2004). Also, further detailed studies
are needed to explore cell death mechanisms of
chloro-imidazoles against T. cruzi as well as other
trypanosomatids.
Due to the urgent need for novel anti-T. cruzi
agents, the application of bioproducts as well as
synthetic agents as therapeutic alternatives must be
further explored with the aim of providing more sel-
ective, safe and aﬀordable drugs for chagasic patients,
especially those millions who are in the chronic stage
of this neglected disease, for which no treatment
exists today.
Fig. 4. Histopathological analysis of representative samples from untreated (A) and treated female mice with 25mg kg−1
(B) and 400mg kg−1 (C,D) doses of viniconazole. Liver sections stained with haematoxylin-eosin (HE) of untreated
animals showing characteristic morphology (A). Liver sections of treated mice exhibit hepatocyte vacuolization (star)
(B,D). 400×.
Fig. 5. In vivo eﬀect of viniconazole on acute mouse
model of Trypanosoma cruzi infection, using Y strain: The
eﬀects of viniconazole (via i.p. – 25–100mg kg−1 day−1
and via p.o route – 100mg kg−1 day−1) and benznidazole
(100mg kg−1 day−1 by p.o.) on parasitaemia (A) and
mortality rates (B) are presented.
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